AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization (Articolo in rivista)

Type
Label
  • AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization (Articolo in rivista) (literal)
Anno
  • 2005-01-01T00:00:00+01:00 (literal)
Alternative label
  • Andreassi M.G.; Botto N.; Cerillo A.G.; Laghi-Pasini F.; Manfredi S.; Ghelarducci B.; Farneti A.; Solinas N.; Biagini A.; Picano E. (2005)
    AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization
    in International journal of cardiology (print)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Andreassi M.G.; Botto N.; Cerillo A.G.; Laghi-Pasini F.; Manfredi S.; Ghelarducci B.; Farneti A.; Solinas N.; Biagini A.; Picano E. (literal)
Pagina inizio
  • 191 (literal)
Pagina fine
  • 195 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 101,2 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note
  • In: \"Int J Cardiol \"101,2005,2,191-195 (literal)
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • CNR-IFC (literal)
Titolo
  • AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization (literal)
Abstract
  • Background: C34T variant of adenosine monophosphate deaminase 1 (AMPD1) gene has been associated with a prolonged survival in heart failure and coronary artery disease, hypothetically linked to an enhanced production of adenosine. Design: Since adenosine administration is a promising approach for the prevention of the ischemia-reperfusion in myocardial revascularization, the aim of this study was to investigate whether the AMPD1 (?) allele is associated with a favorable prognosis after coronary revascularization. In addition, we assessed the association between AMPD1 polymorphism and plasma adenosine levels. Methods: We investigated a total of 161 patients receiving coronary revascularization (70 percutaneous transluminal coronary angioplasty and 91 coronary artery bypass graft). They were investigated for a composite endpoint including recurrent angina, non-fatal MI, target vessel revascularization, heart failure and cardiac death. Plasma adenosine was also measured by high-performance liquid chromatography methods on a subset of 25 patients. Results: During the follow-up period (7.0F0.3 months), the overall combined endpoint accounted for 17 events (10 cardiacrelated deaths, 6 revascularization procedures and 1 congestive heart failure). The composite endpoint was 9.8% for AMPD1 (?) allele carriers vs. 11.5% for non-carriers (log-rank statistic, p = n.s.). In the logistic analysis only low ( V 40%) ejection fraction was an independent predictor of adverse events ( p = 0.01, OR= 3.8, 95% CI 1.3-11.4). Plasma adenosine levels were similar for AMPD1 (?) allele patients (n = 7) as compared for AMPD1 (+) allele (n = 18) subjects (290.5F31.0 vs. 303.3F28.5 nM, p = n.s.). Conclusions: Our results indicate that AMPD1 (?) allele is not associated with a more favorable outcome after coronary revascularization. Alternative cardioprotective pathways of the AMPD1 gene--involving an enhanced chronic long-term production of adenosine--might be responsible for survival. D 2004 Elsevier Ireland Ltd. All rights reserved. (literal)
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Autore CNR di
Prodotto
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Insieme di parole chiave di
data.CNR.it